Related Experiment Video

Updated: Aug 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Current status of anti-angiogenesis therapy for prostate cancer

Juan Antonio Jiménez1, Chinghai Kao, Sudhanshu Raikwar

  • 1Urology Research Laboratory, Departments of Urology, Microbiology and Immunology, Walther Oncology Center, Indiana University Medical Center, Indianapolis, IN 46202, USA.

Urologic Oncology
|May 9, 2006
PubMed

Insights

Prostate cancer is a leading cancer in men. Angiogenesis, the growth of new blood vessels, fuels tumor growth and metastasis, making anti-angiogenesis therapies a promising strategy to overcome treatment resistance.

Area of Science:

  • Oncology
  • Cancer Biology
  • Medical Research

Background:

  • Prostate cancer is a significant cause of cancer mortality and the most diagnosed cancer in men.
  • Current treatments face limitations due to treatment resistance and cancer progression.
  • Tumor growth and metastasis are critically dependent on angiogenesis.

Purpose of the Study:

  • To review the basic science principles of angiogenesis.
  • To explore the application of angiogenesis in developing novel anticancer therapies.
  • To highlight the potential of anti-angiogenesis therapies for prostate cancer.

Main Methods:

  • Review of preclinical studies.
  • Analysis of early clinical evaluations.
  • Synthesis of basic science principles of angiogenesis.

Main Results:

  • Angiogenesis plays a crucial role in prostate cancer progression and metastasis.
  • Anti-angiogenesis therapies show promise as an adjunctive treatment strategy.
  • Overcoming limitations of current therapeutic approaches is a key benefit.

Conclusions:

  • Understanding angiogenesis is vital for developing effective prostate cancer treatments.
  • Anti-angiogenesis therapies offer a promising avenue to combat treatment-resistant prostate cancer.
  • Further research and clinical evaluation are warranted to optimize these therapies.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...